{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:58Z","timestamp":1761630898229,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00262-020-02521-y","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:02:58Z","timestamp":1582196578000},"page":"983-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-0392","authenticated-orcid":false,"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rustem","family":"Gafanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Protsenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ani","family":"Oganesyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurzhan","family":"Nurgaliyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Krasny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufia","family":"Safina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zakurdaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2521_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH (2016) Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 34:539\u2013573","journal-title":"Annu Rev Immunol"},{"key":"2521_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2521_CR3","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1016\/j.clgc.2017.07.017","volume":"15","author":"I Tsimafeyeu","year":"2017","unstructured":"Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R et al (2017) Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 registry. Clin Genitourin Cancer 15(6):e1069\u2013e1072","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2521_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91\u2013104","journal-title":"Nat Rev Immunol"},{"key":"2521_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.gtc.2015.07.004","volume":"44","author":"DE Kaplan","year":"2015","unstructured":"Kaplan DE (2015) Immunopathogenesis of hepatitis C virus infection. Gastroenterol Clin 44:735\u2013760","journal-title":"Gastroenterol Clin"},{"issue":"6","key":"2521_CR6","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.4049\/jimmunol.169.6.3447","volume":"169","author":"H Wedemeyer","year":"2002","unstructured":"Wedemeyer H, He XS, Nascimbeni M, Davis AR et al (2002) Impaired effector function of hepatitis C virus-specific CD8\u2009+\u2009T cells in chronic hepatitis C virus infection. J Immunol 169(6):3447\u20133458","journal-title":"J Immunol"},{"issue":"11","key":"2521_CR7","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM (2017) Immune checkpoint inhibitors in challenging populations. Cancer 123(11):1904\u20131911","journal-title":"Cancer"},{"key":"2521_CR8","volume-title":"Global hepatitis report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization (2017) Global hepatitis report 2017. World Health Organization, Geneva"},{"issue":"3","key":"2521_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK et al (2019) Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016. Hepatology 69(3):1020\u20131031","journal-title":"Hepatology"},{"issue":"4","key":"2521_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","volume":"5","author":"SD Ramsey","year":"2019","unstructured":"Ramsey SD, Unger JM, Baker LH et al (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5(4):497\u2013505","journal-title":"JAMA Oncol"},{"issue":"10","key":"2521_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2217\/imt-2019-0025","volume":"11","author":"M Tagliamento","year":"2019","unstructured":"Tagliamento M, Grossi F, Paolino S et al (2019) Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy 11(10):873\u2013879","journal-title":"Immunotherapy"},{"key":"2521_CR12","first-page":"737389","volume":"2015","author":"D Davar","year":"2015","unstructured":"Davar D, Wilson M, Pruckner C et al (2015) PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV. Case Rep Oncol Med 2015:737389","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"2521_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","volume":"28","author":"A Kothapalli","year":"2018","unstructured":"Kothapalli A, Khattak MA (2018) Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. Melanoma Res 28(2):155\u2013158","journal-title":"Melanoma Res"},{"issue":"10088","key":"2521_CR14","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB Khoueiry","year":"2017","unstructured":"Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389(10088):2492\u20132502","journal-title":"Lancet"},{"issue":"3","key":"2521_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo B-Y, Merle P et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38(3):193\u2013202","journal-title":"J Clin Oncol"},{"issue":"8","key":"2521_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486\u2013499","journal-title":"Nat Rev Immunol"},{"key":"2521_CR17","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.4254\/wjh.v7.i23.2449","volume":"7","author":"ML Salem","year":"2015","unstructured":"Salem ML, El-Badawy A (2015) Programmed death-1\/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 7:2449\u20132458","journal-title":"World J Hepatol"},{"key":"2521_CR18","doi-asserted-by":"publisher","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","volume":"8","author":"D Gardiner","year":"2013","unstructured":"Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R et al (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8:e63818","journal-title":"PLoS One"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02521-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:10:53Z","timestamp":1659057053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02521-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02521-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that the authors have no competing interests, or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}